CertainT® Products and Services Delivered for
2020 Commercial Deployment
Applied DNA Sciences, Inc. (“Applied DNA”, the “Company”,
NASDAQ: APDN), and Nutrition21, LLC (“Nutrition21”), announce the
successful implementation of Applied DNA’s CertainT authenticity
and traceability solution for Nutrition21’s leading sports
supplement ingredient, Nitrosigine®. After extensive product
development, testing and lab-to-production scaleup, both a
multi-year Master Services Agreement and a Trademark Licensing
Agreement (the “Agreements”) were signed to cover commercial
production of Nitrosigine, as well as potential expansion to other
products within the Nutrition21 portfolio. Separately, a Broker
Agreement was also signed between the parties to enable Nutrition21
to represent Applied DNA’s CertainT platform throughout its
extensive network in the dietary supplement market.
“The functional branded ingredient market follows our work in
pharmaceuticals, where we believe transparency and trust are key
tenets to drive consumer confidence. The CertainT platform provides
Nutrition21 proof positive of their ingredients all the way through
to their customers’ finished products and onto retail shelves and
online stores. CertainT supports Nutrition21’s investment in brand
and intellectual property protection for its ingredients and its
customers’ final products,” said Dr. James Hayward, president and
CEO, Applied DNA.
In the highly competitive dietary supplement industry,
Nutrition21 takes brand and intellectual property protection
seriously as an industry role model with a significant focus on
consumer education and quality. It currently holds over 100
domestic and international issued and pending patents for products.
Many support unique claims associated with glucose metabolism,
weight management, brain health, cardiovascular health, and sports
nutrition, among others.
A success in the Nutrition21 product portfolio, Nitrosigine is
the first product covered under the Agreements. Nitrosigine is a
bonded arginine-silicate with FDA New Dietary Ingredient
notification status, clinically shown to significantly boost nitric
oxide levels. Following its introduction to the market, Nitrosigine
has since been integrated into over 250 consumer products and is a
leading branded ingredient in the pre-workout sports nutrition
space.
The CertainT “Tag-Test-Track” platform enables companies and
their supply chains to designate a unique molecular identity tag
that has meaning specific to the tagged material: for example,
geographic facility location, brand, product line or date of
manufacture. This tag can be blended into ingredients, packaging
inks and varnishes in the pharmaceutical, functional food, and
dietary supplements industries. The tag enables its carrier to be
verified for authenticity, proper potency of the mixture and
blending detection, either at the customer or in the Applied DNA
laboratory, depending on application requirements.
“Nutrition21 employs rigorous preclinical and clinical trials as
a key part of its product development strategy to ensure product
safety and consumer trust. The scientific evidence provided by
Applied DNA’s CertainT platform will support these principles with
verification of product compliance through the supply chain,” said
Bill Levi, Vice President of Operations at Nutrition21.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and pre-clinical nucleic acid-based
therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help
protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft,
counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol APDN.
About Nutrition 21
Nutrition21 is a trusted developer and supplier of novel and
clinically substantiated branded ingredients for the nutritional
supplement industry. With a diverse portfolio of patented health
and wellness ingredients, Nutrition21 provides ingredient solutions
to some of the most successful dietary supplement brands in the
marketplace today.
Nutrition 21 currently holds over 100 domestic and international
issued and pending patents for products with highly marketable
claims including: Nitrosigine®, Velositol®, Chromax®, nooLVL®, and
Lepidamax®. Innovative Ingredients. Real Results
For more information, please visit: www.Nutrition21.com.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements describe Applied DNA’s future plans, projections,
strategies and expectations, and are based on assumptions and
involve a number of risks and uncertainties, many of which are
beyond the control of Applied DNA. Actual results could differ
materially from those projected due to our ability to successfully
enter into commercial contracts for the implementation of our
CertainT® platform, the possibility of failure to make timely
payment on its outstanding secured convertible notes and resulting
enforcement by noteholders of remedies on collateral which includes
substantially all of Applied DNA’s assets, the Company’s history of
net losses, limited financial resources, limited market acceptance
and various other factors detailed from time to time in Applied
DNA’s SEC reports and filings, including our Annual Report on Form
10-K filed on December 12, 2019 and our subsequent quarterly report
on Form 10-Q filed on February 6, 2020, and other reports we file
with the SEC, which are available at www.sec.gov. Applied DNA
undertakes no obligation to update publicly any forward-looking
statements to reflect new information, events or circumstances
after the date hereof to reflect the occurrence of unanticipated
events, unless otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200219005665/en/
investor contact: Sanjay M. Hurry, LHA Investor
Relations, 212-838-3777, shurry@lhai.com program contacts:
Judy Murrah, Chief Information Officer, 631-2240-8819,
judy.murrah@adnas.com web: www.adnas.com twitter:
@APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024